サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1646746

患者由来異種移植/PDXモデルの世界市場

Patient Derived Xenograft / PDX Models

出版日
ページ情報
英文 310 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
患者由来異種移植/PDXモデルの世界市場
出版日: 2025年01月31日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 310 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

患者由来異種移植/PDXモデルの世界市場は2030年までに10億米ドルに達する見込み

2023年に4億1,230万米ドルと推定された患者由来異種移植/PDXモデルの世界市場は、2030年には10億米ドルに達し、分析期間2023-2030年のCAGRは14.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるマウスPDXモデルは、CAGR 14.8%を記録し、分析期間終了時には7億9,930万米ドルに達すると予測されています。ラットPDXモデル分野の成長率は、分析期間中CAGR 12.5%と推定されます。

米国市場は2億380万米ドルと推定、中国はCAGR15.4%で成長すると予測

米国の患者由来異種移植/PDXモデル市場は、2023年に2億380万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8,830万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは15.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.5％と13.8％と予測されています。欧州では、ドイツがCAGR約13.5％で成長すると予測されています。

世界の患者由来異種移植（PDX）モデル市場- 主要動向と促進要因のまとめ

PDXモデルはがん研究と医薬品開発にどのような革命をもたらしているか？

患者由来異種移植片（PDX）モデルは、従来の細胞株や動物モデルと比較して、ヒト腫瘍の生物学をより正確に表現することができるため、がん研究や薬剤開発における強力なツールとして登場しました。PDXモデルは、ヒト腫瘍組織を免疫不全マウスに直接移植することによって作成され、腫瘍を増殖させ、生体内で研究することができます。このプロセスにより、がんの挙動や治療反応を理解するために重要な、微小環境や不均一性を含む元の腫瘍の遺伝学的・組織学的特徴が維持されます。PDXモデルは、新しいがん治療法の有効性を試験するための、より現実的なプラットフォームであり、研究者は、腫瘍がどのように進展し、異なる薬剤に反応するかを生体内で観察することができます。これらのモデルは精密医療に不可欠なものとなり、患者に特異的な治療法の同定を可能にし、臨床転帰の改善への希望をもたらしています。個別化がん治療が普及するにつれ、PDXモデルの需要は高まり続け、がん研究に大きな影響を与えています。

なぜ製薬業界はPDXモデルに多額の投資をしているのか？

製薬業界やバイオテクノロジー業界では、臨床試験の成功率を高めるために、前臨床試験で患者由来異種移植（PDX）モデルを採用するケースが増えています。従来の試験管内モデルや動物モデルでは、ヒトの腫瘍が治療にどのように反応するかを正確に予測できないことが多く、臨床試験における腫瘍治療薬の高い失敗率の一因となっています。一方、PDXモデルは、薬剤の有効性と毒性を評価する、より信頼性の高い手段を提供するため、臨床成功の可能性が高まる。製薬会社はPDXモデルを活用することで、より効率的な薬剤スクリーニングを実施し、市場開拓までの時間を短縮し、薬剤開発に関連するコストを削減しています。さらに、PDXモデルからゲノムとトランスクリプトームのデータを統合することで、臨床試験における患者の選択と層別化の指針となるバイオマーカーの同定が可能になります。このような個別化アプローチにより、標的治療や免疫療法の精度が向上し、治療が成功する可能性が高まる。より予測性の高い前臨床モデルの必要性が高まるにつれ、製薬業界によるPDX技術への投資は加速すると予想されます。

PDXモデルは個別化医療とプレシジョン・オンコロジーをどのように強化するのか？

PDXモデルは、個別化医療とプレシジョン・オンコロジーの進歩において極めて重要な役割を果たしています。元の患者腫瘍の生物学的完全性を維持することで、PDXモデルは研究者が腫瘍特異的な薬物反応を調査し、個別化された治療オプションを特定することを可能にします。このことは、患者の転帰が遺伝子変異や分子マーカーによって大きく異なるがんにおいて特に重要です。前臨床研究でPDXモデルを使用することで、科学者は個々の患者に合わせた治療を行うことができ、治療が成功する可能性が高まる。さらに、PDXモデルは併用療法の開発や耐性メカニズムの評価にも使用されており、治療中や再発時に腫瘍がどのように進展するかについての知見を提供しています。患者固有の遺伝子プロファイルに合わせた治療法の開発が重視されるようになるにつれ、PDXモデルは治療効果を予測し、臨床的意思決定を導き、プレシジョン・オンコロジー分野を発展させるために不可欠なツールになりつつあります。

患者由来異種移植（PDX）モデル市場の成長を促す要因は何か？

患者由来異種移植（PDX）モデル市場の成長は、がん研究と医薬品開発を再構築しているいくつかの要因によって牽引されています。遺伝子シークエンシングと分子プロファイリングの技術的進歩により、PDXモデルの作成・解析能力が大幅に向上し、前臨床試験における予測性と価値が高まっています。プレシジョン・メディシンと個別化がん治療への注目の高まりも、PDXモデルが治療反応を評価するための、より正確で患者に特化したプラットフォームを提供する大きな推進力となっています。製薬会社は、医薬品開発の効率を高め、従来の臨床試験に伴う高い失敗率を減らすためにPDXモデルを採用しています。さらに、世界のがん罹患率の上昇と、新規の標的治療に対する需要の高まりが、PDXのような先進的な前臨床モデルの必要性に拍車をかけています。さらに、学術機関、研究機関、製薬企業間の共同研究がPDXプラットフォームの開発と商業化を加速し、市場の成長をさらに促進しています。がん研究を取り巻く環境が進化を続ける中、PDXモデルの需要は拡大し、がん研究と医薬品開発の要としての役割が確固たるものになると予想されます。

セグメント

モデルタイプ（マウスPDXモデル、ラットPDXモデル）、腫瘍タイプ（乳がん、肺がん、前立腺がん、膵臓がん、その他の腫瘍タイプ）、用途（前臨床医薬品開発用途、バイオマーカー解析用途、その他の用途）、最終用途（製薬企業・バイオテクノロジー企業最終用途、CRO/CDMO最終用途、学術・研究機関最終用途）

調査対象企業の例（注目の42社）

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Creative Animodel
  • Crown Bioscience Inc.
  • EPO Berlin-Buch GmbH
  • InnoSer
  • Inotiv, Inc.
  • Oncodesign Services
  • Shanghai Chempartner Co. Ltd.
  • LIDE Shanghai Biotech, Ltd.
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xenopat
  • Xentech

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13873

Global Patient Derived Xenograft / PDX Models Market to Reach US$1.0 Billion by 2030

The global market for Patient Derived Xenograft / PDX Models estimated at US$412.3 Million in the year 2023, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 14.2% over the analysis period 2023-2030. Mice PDX Models, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$799.3 Million by the end of the analysis period. Growth in the Rat PDX Models segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$203.8 Million While China is Forecast to Grow at 15.4% CAGR

The Patient Derived Xenograft / PDX Models market in the U.S. is estimated at US$203.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$88.3 Million by the year 2030 trailing a CAGR of 15.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.5% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Global Patient-Derived Xenograft (PDX) Models Market – Key Trends & Drivers Summarized

How Are PDX Models Revolutionizing Cancer Research and Drug Development?

Patient-derived xenograft (PDX) models have emerged as a powerful tool in cancer research and drug development, offering more accurate representations of human tumor biology compared to traditional cell lines and animal models. PDX models are created by implanting human tumor tissues directly into immunodeficient mice, allowing the tumor to grow and be studied in a living organism. This process preserves the genetic and histological characteristics of the original tumor, including its microenvironment and heterogeneity, which are critical for understanding cancer’s behavior and treatment responses. PDX models provide a more realistic platform for testing the efficacy of new cancer therapies, allowing researchers to observe how tumors evolve and react to different drugs in vivo. These models have become essential for precision medicine, enabling the identification of patient-specific treatments and offering hope for improved clinical outcomes. As personalized cancer therapies gain traction, the demand for PDX models continues to rise, significantly impacting oncology research.

Why Is the Pharmaceutical Industry Investing Heavily in PDX Models?

The pharmaceutical and biotechnology industries are increasingly adopting patient-derived xenograft (PDX) models in preclinical studies to enhance the success rate of clinical trials. Traditional in vitro and animal models often fail to accurately predict how a human tumor will respond to a treatment, contributing to the high failure rate of oncology drugs in clinical trials. PDX models, on the other hand, provide a more reliable means of evaluating drug efficacy and toxicity, thus improving the chances of clinical success. Pharmaceutical companies are leveraging PDX models to conduct more efficient drug screening, reduce time to market, and lower the costs associated with drug development. Furthermore, the integration of genomic and transcriptomic data from PDX models allows for the identification of biomarkers that can guide patient selection and stratification in clinical trials. This personalized approach enhances the precision of targeted therapies and immunotherapies, increasing the likelihood of successful treatment outcomes. As the need for more predictive preclinical models grows, the pharmaceutical industry's investment in PDX technology is expected to accelerate.

How Are PDX Models Enhancing Personalized Medicine and Precision Oncology?

PDX models are playing a pivotal role in the advancement of personalized medicine and precision oncology. By maintaining the biological integrity of the original patient tumor, PDX models allow researchers to study tumor-specific drug responses and identify personalized treatment options. This is particularly important in cancers where patient outcomes vary widely depending on genetic mutations and molecular markers. The use of PDX models in preclinical research enables scientists to tailor therapies to individual patients, increasing the likelihood of successful treatment. Additionally, PDX models are being used to develop combination therapies and evaluate resistance mechanisms, offering insights into how tumors may evolve during treatment and relapse. With the rising emphasis on developing therapies that are tailored to the unique genetic profiles of patients, PDX models are becoming indispensable tools for predicting treatment responses, guiding clinical decision-making, and advancing the field of precision oncology.

What Factors Are Driving Growth in the Patient-Derived Xenograft (PDX) Models Market?

The growth in the patient-derived xenograft (PDX) models market is driven by several factors that are reshaping cancer research and drug development. Technological advancements in genetic sequencing and molecular profiling have significantly enhanced the ability to create and analyze PDX models, making them more predictive and valuable in preclinical testing. The increasing focus on precision medicine and personalized cancer therapies is another major driver, as PDX models offer a more accurate and patient-specific platform for evaluating treatment responses. Pharmaceutical companies are adopting PDX models to improve the efficiency of drug development and reduce the high failure rates associated with traditional clinical trials. Furthermore, the rise in cancer incidence worldwide and the growing demand for novel, targeted therapies are fueling the need for advanced preclinical models like PDX. Additionally, collaborations between academic institutions, research organizations, and pharmaceutical companies are accelerating the development and commercialization of PDX platforms, further driving market growth. As the landscape of oncology research continues to evolve, the demand for PDX models is expected to expand, solidifying their role as a cornerstone of cancer research and drug development.

SCOPE OF STUDY:

The report analyzes the Patient Derived Xenograft / PDX Models market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Model Type (Mice PDX Models, Rat PDX Models); Tumor Type (Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Other Tumor Types); Application (Pre-Clinical Drug Development Application, Biomarker Analysis Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Creative Animodel
  • Crown Bioscience Inc.
  • EPO Berlin-Buch GmbH
  • InnoSer
  • Inotiv, Inc.
  • Oncodesign Services
  • Shanghai Chempartner Co. Ltd.
  • LIDE Shanghai Biotech, Ltd.
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xenopat
  • Xentech

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Rise in Cancer Incidence Fosters Growth in Patient Derived Xenograft / PDX Models Market
    • Select Cancer Statistics
    • EXHIBIT 1: Total Number of New Cancer Cases by Type: 2022
    • EXHIBIT 2: Total Number of Cancer Deaths by Type: 2022
    • EXHIBIT 3: Cancer Incidence by Region: 2022
    • EXHIBIT 4: Cancer Mortality by Region: 2022
    • Evolution & Relevance of PDX Models
    • Establishing PDX Models
    • PDX Models: Key Applications
    • Economic Frontiers: Trends, Trials & Transformations
    • EXHIBIT 5: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
    • EXHIBIT 6: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
    • EXHIBIT 7: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
    • Competitive Scenario
    • EXHIBIT 8: Patient Derived Xenograft / PDX Models - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E)
    • Global Market Overview and Prospects
    • Patient-Derived Xenograft (PDX) Models to Gain More Ground & Become a Buzz Market
    • Delving into Paradigm Segments of Global Patient-Derived Xenograft Model Market
    • Preclinical Drug Development as Key Application
    • Patient-Derived Xenograft Model Market on the March with Interplay of Dynamic Factors
    • Market Drivers
    • Market Opportunities
    • Market Restraints
    • Market Challenges
    • Developments Trending Big on Global Patient-Derived Xenograft Model Market
    • EXHIBIT 9: Select Recently Announced Scientific Research PDX Models & Biobanks of Different Cancer Types
    • Regional Market Analysis
    • North America Remains at Forefront, while Asia-Pacific Dazzles with Steamy Growth on Global PDX Model Market
    • Market Outlook
    • Recent Market Activity
    • Influencer/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Patient-Derived Xenograft (PDX) Models Transform Personalized Medicine
    • EXHIBIT 10: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • PDX Models Paving the Way for Targeted Therapies
    • The Surge in Investment for Cancer Research to Propel Market Growth
    • Patient-Derived Xenograft (PDX): A Pulsating Tool in the Cancer Research Arsenal
    • EXHIBIT 11: Cancer Research Funding Scenario (2024): Funding Investments & Grants by Major Entities
    • Harnessing the Power of OMICs Technologies Through PDX Models
    • Advancing Predictive Biomarker Discovery with PDX Models
    • Increased Focus on Drug Resistance Studies in Oncology Spurs Demand for Patient-Derived Xenograft Models
    • PDX Models Advance the Evaluation of Treatment Efficacy and Toxicity
    • Technological Advancements Driving Innovation in PDX Models
    • The Intersection of PDX Models and 3D Printing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Patient Derived Xenograft / PDX Models Market Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Mice PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Mice PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Rat PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Rat PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Tumor Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Other Tumor Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Pre-Clinical Drug Development Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biomarker Analysis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Biomarker Analysis Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for CROs / CDMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for CROs / CDMOs End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World 7-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • Market Analytics
    • TABLE 30: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • JAPAN
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • CHINA
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • Market Analytics
    • TABLE 54: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • EUROPE
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • Market Analytics
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • FRANCE
    • TABLE 72: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • GERMANY
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • ITALY
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • UNITED KINGDOM
    • TABLE 96: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 101: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 103: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • Market Analytics
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030

IV. COMPETITION